Ben R. Bronstein
Independent DirectorDr. Ben R. Bronstein, M.D., serves as Member of Advisory Board of Slater Technology Fund. He is responsible for Life Sciences sector at the firm. He served as the interim Chief Medical Officer at Sentien Biotechnologies, Inc. from 2016 to 2017. He served as the Chief Executive Officer at Aldeyra Therapeutics, then known as Neuron Systems from 2010 to 2011. Previously, he served as Chief Medical Officer of Stealth BioTherapeutics, Inc. Dr. Bronstein is an independent consultant providing advisory services to companies in the life sciences industry. Prior to his consulting role, Dr. Bronstein served as Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. from 2017 to 2018. Dr. Bronstein has founded or held senior management positions at several venture-backed life science companies including BioSurface Technology, Inc. In 2006, he Co-Founded Vidus Ocular, Inc. and served as its President and Chief Operating Officer. Dr. Bronstein was a Co-Founder of Access BridgeGap Ventures and served as its Senior Vice President. He served as a Managing Director at Zero Stage Capital Co. Dr. Bronstein has also served as a Principal at Zero Stage Capital Co., which he joined in 1999. He was responsible for life science investments at the firm. He later served as Vice President of R&D-Devices at OPKO Health. He served as the interim Chief Executive Officer at Spherics, Inc. Before this, he was the Founder, President and Chief Executive Officer at Peptimmune, Inc. Earlier, Dr. Bronstein served as a Senior Executive and Executive Vice President at Seaflower Associates Inc. He started his entrepreneurial career in 1989 at Genzyme Tissue Repair where he served as a Vice President of Medical Affairs and Medical Director. Dr. Bronstein began his professional career as a Staff Pathologist at the Massachusetts General Hospital and was on the faculty of Harvard Medical School. He serves as a Director of RenaMed Biologics and Nephros Therapeutics Inc. He served as Chairman at Cleveland Diagnostics, Inc. until January 2024. Dr. Bronstein serves on Scientific Advisory Board of Biolink Corp. and an Advisor to the Board of Directors of HydroCision Inc. He serves as a Director of the Enterprise Development Resource Center and Slater Center for Biomedical Technology. He has been Independent Director of Aldeyra Therapeutics, Inc. since June 2010. Dr. Bronstein serves as Member of the Advisory Board at Echelon Ventures. He is a Director of a public life science company. He served as Director at Elicio Therapeutics Inc. He served as a Director of CytoPherx, Inc., HydroCision, Inc., PathoGenetix, Inc. and Biotrove, Inc. He served as a Director of eXIthera Pharmaceuticals, Inc. He served as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard University. He holds an appointment as a Visiting Assistant Professor of Pathology and Laboratory Medicineat Weill Cornell Medical College. He has more than a decade of experience as a biotech entrepreneur, corporate executive and Advisor to biomedical and scientific companies. He has spent the past 29 years in entrepreneurial and management roles in life science companies and venture capital firms. He is a board-certified pathologist and dermatopathologist, with over 20 publications. He is also a member of the Scientific Advisory Committee of the Daedalus Fund of Weill Cornell Medicine from which he resigned (retired) effective January 2020. Dr. Bronstein received an M.D. degree, M.B.A. (with high honors) and A.B. in Biology (magna cum laude), all from Boston University.
Positions
- Company NameAldeyra Therapeutics, Inc.Stock CodeALDXPositionIndependent DirectorColleagues
- TCTodd C. BradyCEO, President & Director
- RHRichard Huntington DouglasIndependent Chair of the Board
- MAMichael AlfieriHead of Finance and Principal Financial & Accounting Officer
- DBDavid BurkeHead of Investor Relations
- ALAdam LazorchakDirector of Translational Sciences & Non-Clinical Development
- GMGary M. PhillipsIndependent Director
- DMDarlene M. Deptula-HicksIndependent Director
